Literature DB >> 31032651

Are risk minimization measures for approved drugs in Europe effective? A systematic review.

Esther Artime1, Nawab Qizilbash1,2, Macarena Garrido-Estepa3, Pareen Vora4, Montse Soriano-Gabarró4, Alex Asiimwe4, Stuart Pocock2.   

Abstract

Objectives: The effectiveness of risk minimization measures (RMMs) requires evaluation. This study aims to evaluate the results of cross-sectional surveys assessing the effectiveness of RMMs in Europe (EU RM Surveys) and review the regulatory consequences.
Methods: The authors searched for study reports and manuscripts of completed EU RM surveys in the EU PAS Register, MEDLINE, and Google between 01/2011 and 01/2018. Regulatory responses were extracted from Assessment Reports. Random effects models to combine proportions were used.
Results: Twenty-four EU RM surveys were identified. Twenty-three studies targeted health-care professionals (HCPs). The pre-specified sample size was reached in 52% of studies. HCP participation was 5% defined as completers/invited and 89% for completers/eligible. Receipt of materials was recalled by 60% of HCPs and 77% of items scored knowledge >60%. Eight studies targeted patients/caregivers. The pre-specified sample size was reached in only two. Participation was 93%, defined as completers/eligible. Materials were received by 50-80% of patients and read by over 90%. Patients only scored knowledge >60% in 38% of items. Further action was requested by regulators in 59% of studies.
Conclusion: Surveys are necessary to evaluate many RMMs. Challenges remain in the design, conduct, and reporting of these studies which may benefit from the use of standard definitions and further guidance on reporting. EU PAS Register: http://www.encepp.eu/encepp/viewResource.htm?id=23435.

Entities:  

Keywords:  EU PAS Register; GVP XVI; PRAC; Risk minimization; final study reports; meta-analysis; post-authorisation safety study; process indicators; regulatory decisions; surveys; systematic review

Mesh:

Year:  2019        PMID: 31032651     DOI: 10.1080/14740338.2019.1612875

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  8 in total

1.  Survery of healthcare professionals to assess the awareness, knowledge and self-reported behavior regarding recent fluoroquinolones safety issues.

Authors:  Madalina Huruba; Andreea Farcas; Daniel Corneliu Leucuta; Mariana Sipos; Cristina Mogosan
Journal:  Med Pharm Rep       Date:  2021-10-30

2.  Agomelatine Drug Utilisation Study in Selected European Countries: A Multinational, Observational Study to Assess Effectiveness of Risk-Minimisation Measures.

Authors:  Emmanuelle Jacquot; Estelle Collin; Amy Ladner; Anita Tormos; Lynne Hamm; Susana Perez-Gutthann; Lia Gutierrez; Costel Chirila; Nicolas Deltour
Journal:  Pharmaceut Med       Date:  2019-08

3.  Pharmacists' perception of educational material to improve patient safety: A cross-sectional study on practices and awareness in Germany.

Authors:  André Said; Leonard Freudewald; Natalie Parrau; Matthias Ganso; Martin Schulz
Journal:  Medicine (Baltimore)       Date:  2021-03-19       Impact factor: 1.817

4.  Evaluating the Effectiveness of Apixaban Additional Risk Minimisation Measures Using Surveys in Europe.

Authors:  Steve Mayall; Randip Kahlon; Imad Al-Dakkak; Sophie W Shen
Journal:  Pharmaceut Med       Date:  2021-03-04

5.  Improving the Safety of Medicines via Digital Technology: An Assessment of the Scope and Quality of Risk Minimization Websites in the United States and United Kingdom.

Authors:  Meredith Y Smith; Sarah Frise; Jane Feron; Ryan Marshall
Journal:  Drug Saf       Date:  2022-03-05       Impact factor: 5.606

6.  Effectiveness of Additional Risk Minimization Measures for Atezolizumab in the European Union.

Authors:  Hina Patel; Thanh G N Ton; Jessica Davies; Simon Fear; Carolin Block; Kunihiko Tanaka; Danny Gonzalez; Roger Mutter; Noelia Alfaro-Oliver; Ignacio Mendez; Nawab Qizilbash
Journal:  Pharmaceut Med       Date:  2021-12-07

7.  Patient Preferences for Rituximab Additional Risk Minimization Measures: Results From an International Online Survey.

Authors:  Kristyna Schneiderova; Nathalie Bere; Doris Irene Stenver; Sabine M J M Straus
Journal:  J Patient Saf       Date:  2021-10-05       Impact factor: 2.243

Review 8.  A review of the sampling methodology used in studies evaluating the effectiveness of risk minimisation measures in Europe.

Authors:  Laurence Sophie Jouaville; Tulika Paul; Mariana Ferreira Almas
Journal:  Pharmacoepidemiol Drug Saf       Date:  2021-06-24       Impact factor: 2.890

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.